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Abstract: Older adults with depression often present with signs and symptoms indicative of
functional or cognitive impairment. These somatic symptoms make evaluating and treating
depression in older adults more complex. Late life depression (LLD), depression in adults over
the age of 65, is more frequently associated with cognitive changes. Cognitive impairment in
LLD may be a result of the depressive disorder or an underlying dementing condition. Memory
complaints are also common in older adults with depression. There is a wide range of cognitive
impairment in LLD including decreased central processing speed, executive dysfunction,
and impaired short-term memory. The etiology of cognitive impairment in LLD may include
cerebrovascular disease, a signiﬁcant risk factor for LLD, which likely interrupts key pathways
between frontal white matter and subcortical structures important in mood regulation. Because
depressive symptoms often coexist with dementia, it is important to determine the temporal
relationship between depressive symptoms and cognitive change. If depressive symptoms
pre-date the cognitive impairment and cognitive symptoms are mild and temporary, LLD is
the likely etiology of the cognitive impairment. If cognitive changes appear prior to depressive
symptoms and persist after LLD is successfully treated, an underlying dementia is more likely.
Clinicians should be exclude common conditions such as thyroid disease which can contribute
to depressive symptoms and cognitive impairment prior to treating LLD. Both antidepressants
and psychotherapy can be effective in treating LLD. Subsequent evaluations following treatment
should also reassess cognition.
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Depression in older adults is a serious illness and may lead to impaired physical function,
increased mortality, and unwarranted use of health care resources. Late life depression
(LLD), depression occurring in patients over age 65, remains under-diagnosed and
under-treated. The prevalence of LLD varies depending on the population studied,
affecting up to 9% of community dwelling elderly but 25% of institutionalized elderly
and those recently hospitalized.1,2 Compared to adults with depression earlier in life
(early onset depression), patients with late-onset depression (ﬁrst episode after age 65)
are less likely to have a family history of depression and are likely to have signiﬁcant
comorbidities, especially cardiovascular diseases. Consequently, environmental factors
and lifestyle factors may be associated with the development of LLD.
Patients with LLD often present with cognitive complaints or cognitive deﬁcits.
These cognitive changes may occur as a consequence of depression or may indicate a
coexisting condition such as Alzheimer’s disease or Parkinson’s disease. Establishing
whether depression is the primary cause of cognitive change or whether a concomitant
dementing illness exists is important in the management of the disease. Since more
than 75% of care for LLD is provided by non-psychiatrists, it is imperative that primary
care providers are able to diagnosis LLD and distinguish it from other diseases which
can present with similar symptoms.
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Pathophysiology
LLD is thought to be pathophysiologically different from
depression in young adults as it is often associated with
comorbid illnesses. Risk factors for LLD include stressors
such as living alone, chronic pain, and comorbid illnesses
such as cardiovascular disease. See Table 1 for additional
risk factors.
Over the last two decades, studies have identified
important biological and cognitive correlates of depression
in late life. Among these are associations with morphologic
abnormalities in key brain structures and neuropsychological
abnormalities in executive function and memory. 3–5
Several studies have found a strong association between
cerebrovascular risk factors and LLD.6,7 In some individuals,
vascular disease may contribute to the development of a late
life depression syndrome by interrupting the connections
between frontal white matter pathways and subcortical
structures (such as basal ganglia) involved in mood.8–10
The term vascular depression has emerged from
imaging findings of white matter hyperintensities
associated with LLD. Studies have found that patients
with LLD and structural magnetic resonance imaging
(MRI) evidence of cerebrovascular disease have greater
neuropsychological impairment on testing.11,12 We found
a wide range of disruption of cognitive functioning in
LLD, in particular, processing speed was a core cognitive

Table 1 Risk factors for late life depression28,29
Gender (Women are more likely than men)
Marital status (widowed, divorced, single)
Social isolation
Alcohol use
Medications
•

Chronic benzodiazepine use

•

Narcotics

•

Antihypertensives (beta blockers)

•

Interferon alpha

Death of spouse or close loved-one
Severe and chronic pain
Medical illnesses

deﬁcit.13 It is hypothesized that cerebrovascular ischemia
disrupts brain circuitry and results in depression as well
as neuropsychological impairment. Clinical factors that
might be linked to worse neuropsychological performance
in LLD, include depression severity, comorbid anxiety,
vegetative symptoms, number of prior episodes, age and
late age of depression onset.14,15 Cognitive impairment
in LLD has also been shown to be greater in late-onset
depression.16

Diagnosis
Although the diagnostic criteria for LLD are the same as
depression in younger adults, patients with LLD often
present with more somatic symptoms. Making a diagnosis
of LLD can be difﬁcult for many reasons including more
subtle presentations in older adults, coexisting medical
illnesses, and reluctance to self-report symptoms. In addition
to the obvious signs of depression, patients with LLD may
have nonspeciﬁc symptoms which may be confused with
physical illness such as psychomotor slowing, fatigue, and
increased pain.
Additionally, many clinicians use the term ‘depression’
not only in reference to a major depressive episode (MDE),
but also to describe a symptom or other nonspeciﬁc syndrome.
The diagnostic criteria for depression/MDE and special
considerations in older adults are presented in Table 2.

Table 2 DSM-IV diagnostic criteria for episode of major depression
and special considerations in late life depression
Five or more of the following 9 symptoms present nearly every day for at
least 2 weeks (at least one symptom being depressed mood or diminished
interest or pleasure):
1. Depressed mood
2. Markedly diminished interest or pleasure in almost all activities
3. Fatigue or loss of energy
4. Feelings of worthlessness or excessive or inappropriate guilt
5. Clinically significant weight loss or weight gain or decrease in appetite
6. Insomnia or hypersomnia
7. Observable psychomotor agitation or retardation
8. Diminished ability to think or concentrate, or indecisiveness
9. Recurrent thoughts of death or suicidal ideation

•

Cancer

•

Hypothyroidism

•

Stroke

•

Dementing Illnesses- (Alzheimer’s disease, Parkinson’s disease)

•

Myocardial Infarction

•

Hip fracture

• Symptoms from chronic medical illnesses (fatigue, weight loss) may
overlap with depressive symptoms

•

Coronary artery bypass surgery

• Older men have highest rates of suicide
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Special considerations for older adults with depressive symptoms
• Coexisting memory complaints are common
• Many older adults believe depression is normal with aging
• Psychosocial risk factors for depression are common
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Diagnosing LLD can be especially challenging in those
with cognitive impairment. Whether cognitive changes in
the setting of LLD signals a coexisting illness or is simply
an effect of the depression is a complex question. Some
older adults present with cognitive complaints yet meet
criteria for depression; similarly, older adults may report
depressed mood but are actually demented. Although
pseudodementia can be caused by LLD, pseudodementia
is relatively uncommon and depression commonly coexists
with dementing illnesses including 40% of Parkinson’s
disease, 20%–30% of Alzheimer’s disease, and 30%–60%
of stroke patients.
The evaluation of depressive symptoms and cognitive
changes must include a complete history and physical
with a detailed neurological exam to determine whether
focal deﬁcits or parkinsonism are present. Laboratory tests
for thyroid disease, B12 deficiency, anemia, and renal
impairment should be performed to exclude an underlying
medical illness. A brief interview with the patient’s spouse,
adult child, other relative or friend is extremely helpful
in determining whether the patient’s symptoms are most
likely depression or an underlying dementia.17 If depressive
symptoms began prior to or concurrent with cognitive
changes, depression may be more likely. If cognitive changes
are more consistent and preceded the depressive symptoms,
more consideration of a dementing illness is warranted.
Following the history and physical, depressive
symptoms should be assessed using a screening tool.
Several screening tools have been successfully used to
identify LLD. These screens can help detect depressive
symptoms but they should not be used independently to
diagnose LLD. Patients who screen positive should be
further interviewed to determine whether diagnostic criteria
for depression are met.
Although there are numerous screening instruments,
it is important to identify screening tools that have
been validated and are easy to administer and interpret.
The Geriatric Depression Scale (GDS), Patient Health
Questionnaire-9 (PHQ-9), and the Center for Epidemiologic
Studies Depression Scale (CES-D) are all useful for
identifying depressive symptoms in the elderly.
The GDS has been studied in multiple settings and was
designed speciﬁcally for older adults.18 The ﬁfteen-item
version has demonstrated good operating characteristics
across the full spectrum of elderly populations. Five or more
depressive symptoms suggest the diagnosis of depression.
The instrument can be self administered or given by the
clinician/staff.
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The PHQ-9 was developed speciﬁcally for use in primary
care settings and has demonstrated validity and reliability.19
It encompasses all nine DSM-IV criteria for major depression
and has been shown to be a reliable measure of depression
treatment outcomes in a large study of older adults. The full
PHQ-9 is shown in Figure 1. The tool can also be used to
assess response to treatment in individual patient care.
The CES-D is commonly used in primary care settings
for the assessment of depressive symptoms.20 Although it
has been used in older adults, the instrument was developed
for research not for the clinical setting so individual scores
must be interpreted with caution.
Assessment of cognitive performance using a tool such as
the Mini-Mental State Exam, the Short Blessed Test, or other
cognitive screening tool should be performed. While these
screening tools alone should not be used to determine whether
the patient is cognitively impaired, they may be useful in
following cognitive performance during and after treatment
of depression. If cognitive impairment persists after depressive symptoms improve, additional evaluations to exclude
underlying or coexisting dementia should be pursued. This
evaluation should include brain imaging to exclude stroke,
tumor, and normal pressure hydrocephalus.

Addressing psychosocial risk factors
Psychosocial risk factors for LLD are common and many
older adults with depression often have more than one risk
factor. Common psychosocial factors in LLD include loss
of function or physical disability, bereavement, caregiver
stress, lack of social support, and change in societal roles (ie,
retirement).21 It is important to identify these risk factors and
determine their effect on LLD. Unfortunately, there are no
existing tools that accurately predict risk of LLD based on
psychosocial risk factors. The clinician should ask patients
with depression whether recent life events are contributing
to depressive symptoms as patients with signiﬁcant psychosocial risk factors may beneﬁt more from psychotherapy.

Treatment
After the careful diagnosis of LLD, the initial treatment
of choice in the primary care setting is the use of
antidepressant medications. There is also good evidence
for the efﬁcacy of psychotherapy as a treatment option;22
however, this requires a specialist referral. The overarching
principal, as in other areas of geriatric medicine, is to use
a low starting dose and to slowly increase the dose as
necessary. It is usual to start treatment with one half of
the younger adult starting dose and to make subsequent
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Name ______________________ Date _________
More
Over the last 2 weeks, how often have you been

Not at

Several

Nearly
than half

bothered by any of the following problems?

all

days

every day
the days

1. Little interest or pleasure in doing things

0

1

2

3

2. Feeling down, depressed, or hopeless

0

1

2

3

0

1

2

3

4. Feeling tired or having little energy

0

1

2

3

5. Poor appetite or overeating

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

3. Trouble falling or staying asleep, or sleeping too
much

6. Feeling bad about yourself—or that you are a
failure or have let yourself or your family down
7. Trouble concentrating on things, such as reading
the newspaper or watching television
8. Moving or speaking so slowly that other people
could have noticed? Or the opposite—being so fidgety
or restless that you have been moving around a lot
more than usual
9. Thoughts that you would be better off dead or of
hurting yourself in some way
(For office coding: Total Score ____ = ____ + ____ + ____)

If you checked off any problems, how difficult have these problems made it for you to do your
work, take care of things at home, or get along with other people?
Not difficult at all

Somewhat difficult

Very difficult

Extremely difficult

□

□

□

□

Scoring—add all checked boxes on PHQ-9.
Total Score Depression Severity
0–4 None
5–9 Mild depression
10–14 Moderate depression
15–19 Moderately severe depression
20–27 Severe depression

From the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire (PRIME-MD
PHQ). PHQ-9 © 1999 Pfizer Inc. All rights reserved. Reproduced with permission from Pfizer Inc.
Figure 1 PHQ-9 for the assessment of depression.
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titrations in small dose intervals. Selective serotonin
reuptake inhibitors (SSRIs) are the most commonly used
ﬁrst line treatment for depression including LLD as they
have relatively low toxicity and high tolerability.23,24 Of
the SSRIs, citalopram was used in a large NIH funded
multi-center trial, the STAR*D trial, for the treatment
of depression that included patients with late life depression.24 Citalopram was chosen for its once a day dosing,
lack of discontinuation side-effects and low potential for
drug-drug interaction, all attractive characteristics in LLD.
Other choices include escitalopram with a similar proﬁle
as citalopram and sertraline (favorable proﬁle at low dose)
amongst other SSRIs (Table 3). The newer generation of
antidepressants has a more diverse mechanism of action
than the selective serotonin inhibition. These can be used
as ﬁrst line treatment, although the data supporting its
use in LLD is limited (Table 3). The older antidepressant
medications include the tricyclic antidepressants such
as desipramine and the monoamine oxidase inhibitors
such as selegiline have limited use in the elderly. These
medications have signiﬁcant side effect liability and are
best prescribed and monitored by a psychiatrist.

Inadequate trial duration and suboptimal dosing are
the two most common reasons for low treatment response.
Adequate trial duration is at least 8 weeks of treatment
and the dose should be carefully increased to the upper
dosage range, as tolerated, if patient shows no response.
Also, SSRI and other antidepressant medications take
at least two weeks before any improvement is noticed,
with optimal reduction in symptoms taking as long as
8–12 weeks. It is therefore prudent to wait for a minimum
of two weeks before dose increases. It is best to discuss
this lag period with the patient and their caregivers in the
process of obtaining informed consent; also, the concern
that the SSRI group of medications may cause increased
suicidal ideations should be made explicit. All antidepressants can cause GI symptoms during the initial treatment
period and are usually self limiting; further reduction of
dosage or a switch to another agent can remedy this. Sexual
dysfunction may be another of the side effects that should
be discussed. Table 4 includes a list of common side effects
of some antidepressants.
Along with the medication, it is important to assess the
adequacy of social support, any impediment to medication

Table 3 Select antidepressants
Antidepressant

Initial dose

Dosage range

Pharmacokinetics

Comments

1. Citalopram
(Celexa)

10 mg

20–40 mg

Weak inhibitor of CYP450
2D6

Well tolerated. Tramadol may
increase risk of seizure

2. Escitalopram
(Lexapro)

5 mg

10–20 mg

No significant action on
CYP450

Well tolerated. Caution if history of
seizure

3. Sertraline
(Zoloft)

25 mg

50–200 mg

Inhibits CYP450 2D6 and
3A4 (weakly at low doses)

Caution with use of HMG CoA
reductase inhibitors. Tramadol,
Alprazolam, Thioridazine

4. Fluoxetine
(Prozac)

5 mg

10–40 mg

Inhibits CYP450 2D6 and
3A4

Long half life (2 weeks). Other
cautions as for sertraline

10 mg

10–40 mg

Inhibits CYP450 2D6

Caution with thioridazine, drugs
with anticholinergic properties and
theophylline

6. Bupropion SR
(Wellbutrin)

100 mg

100–400 mg

Inhibits CYP450 2D6

Increases risk for seizure. Caution
with levodopa and amantadine

7.Venlafaxine XR
(Effexor XR)

37.5 mg

75–225 mg

No significant action on
CYP450

Increased BP that is dose dependent.
SIADH, Hyponatremia. Do NOT use
in uncontrolled glaucoma

8. Duloxetine
(Cymbalta)

20 mg

40–60 mg

Inhibits CYP450 2D6 and
1A2

Monitor BP as it may increase. Do
NOT use in uncontrolled glaucoma
or with thioridazine

9. Mirtazapine
(Remeron)

7.5 mg

15–45 mg

No significant action on
CYP450

May increase cholesterol, cause
photosensitivity and rarely lower
WBC count.

SSRI:

5. Paroxetine
(Paxil)

Others:

Clinical Interventions in Aging 2009:4
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Table 4 Common side effects of SSRIs
Nausea
Vomiting
Diarrhea
Anorexia (early in the treatment)
Sedation
Sexual dysfunction
Insomnia
Hyponatremia

compliance and other illnesses that may adversely impact
depression. Interventions to improve social support may
include educating the family about depression and the need
for more close monitoring and encouragement to attend
spiritual activities. Compliance with medication may be
enhanced with the use of a pillbox and involvement of a
caregiver. Optimal treatment of patients’ co-morbid medical
illnesses will contribute to patients’ improved sense of
well-being and mental health.

When to refer
Severity
The severity of depression will determine the aggressiveness
of the treatment approach. Any suicidal ideation, weight
loss due to decreased food intake, low ﬂuid intake, and
psychomotor retardation alongside intense low mood will
require a more aggressive management strategy. Such severe
depression will warrant an aggressive treatment strategy and
may require the use of electroconvulsive therapy (ECT),
combination antidepressant therapy, use of tricyclics or
monoamine oxidase inhibitors, all requiring prompt referral
to a psychiatrist. The psychiatrist may treat this patient
alongside the primary care physician or serve as a consultant
who does crisis intervention. The primary care provider may
continue managing the patient’s depression once the severity
of depression has lessened and patient has achieved response
or preferably, remission.

Psychotherapy
The efﬁcacy of psychotherapy is well supported by literature for treatment of mild to moderate depression.22 Patients
who wish to avoid or delay antidepressants and those with
signiﬁcant psychosocial risk factors may be good candidates for
psychotherapy. Both cognitive behavioral therapy (CBT) and
interpersonal psychotherapy (IPT) are effective in older adults
with depression including those with cognitive impairment.
CBT focuses on modifying everyday thoughts and behaviors
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by positively influencing emotions. Distorted thinking
is recognized and replaced with more realistic substitute
ideas. In IPT, education about depression is provided and
interpersonal events that could be associated with depressive
symptoms are explored. Possible solutions are also pursued.
A licensed mental health therapist will provide appropriate
psychotherapy.

Failure of first-line antidepressant
medication
If patient does not respond to the ﬁrst-line antidepressant
medication treatment, it may be best to obtain a psychiatrist
intervention. The treatment options at this stage include use
of augmentation with another antidepressant/psychotherapy
or switching to another agent. This becomes a complex issue
and a specialist will be able to offer a larger spectrum of
treatment options. Failure of antidepressant therapy may also
indicate an underlying cognitive impairment.

Recurrent or relapsing depression
Longitudinal studies indicate that a signiﬁcant number of
patients are at a high risk of relapse even after successful
treatment.25 Biological and social factors both affect an
elderly individual’s long-term course of depression, both in
the acute phase and longer term. Although there is signiﬁcant
individual variability in disease course in patients with LLD,
a greater number of previous depressive episodes increases
the risk of future relapse and decreases time to relapse.26,27
Depressed elderly individuals who do not respond
to ﬁrst-line antidepressant therapy, who exhibit greater
residual depressive symptoms, or who require a longer
time to respond to treatment are at higher risk of relapse.
Discontinuation of maintenance antidepressant therapy in
elderly individuals also carries a high risk. Accordingly, a
referral to a psychiatrist may improve treatment outcomes.
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